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fractionated radiation treatment is assumed to be decisive 
for treatment success. [18F]-Fluoro-Misonidazole PET (F-
MISO-PET) allows noninvasive assessment of hypoxia during 
treatment. The purpose of the present study was to 
noninvasively assess the time course of tumor hypoxia. 
 
Material and Methods: A prospective serial imaging study 
was conducted in patients undergoing definitive 
chemoradiation (dRCTx, total dose 70Gy) for locally 
advanced HNSCC, accompanied by cisplatin in weeks 1, 4 and 
7. Tumor hypoxia was assessed by F-MISO-PET by static scans 
acquired 2.5 h p.i. Tumor volumes were determined for FDG 
PET/CT scans and the coregistered F-MISO/CT scans. At 
baseline MRI, FDG-PET/CT and F-MISO-PET were acquired 
(week 0). Additional F-MISO-PET/CT scans were acquired in 
treatment weeks 2 and 5. Normal sample distribution was 
confirmed with Shapiro-Wilk test. Unpaired t-test analysis of 
the mean SUVmax(tumor)/SUVmean(muscle) ratios of F-MISO-
PET in weeks 0, 2 and 5 were performed. Significance-level 
was defined as p<0.005. 
 
Results: Between 2012 and 2014 18 patients (16 men, two 
women, mean age 60 years), treated for HNSCC with dRCTx 
were included. All received a total dose of 70 Gy in 35 
fractions. Concomitant cisplatin chemotherapy was 
administered in weeks 1, 4 and 7. 14 patients had all F-MISO-
PET scans, while 4 had two F-MISO-PET scans (week 0, 5). 
The mean follow-up time was 14.6 months (range: 4 - 28 
months). Mean SUVmax(tumor)/SUVmean(muscle) in weeks 0, 
2 and 5 were 1.9 (n=18, SD ± 0.1), 1.5 (n=14, SD ± 0.1) and 
1.2 (n=18, SD ± 0.1), respectively. Unpaired t-test for 
SUVmax(tumor)/SUVmean(muscle) between week 0 and 5 
was performed, showing a singnificant decrease (p<0.0001). 
Between weeks 0 and 2 (p=0.0346) and between weeks 2 and 
5 the decrease again was highly significant (p=0.0113). In two 
patients no residual hypoxia was measured in week two, 
resulting in SUVmax(tumor)/SUVmean(muscle) =1.0. In week 
5 this was found in seven patients. In two patients hypoxia 
had increased in week 2 but decreased in week 5 compared 
to pre-treatment measurements. In one patient hypoxia had 
increased by the end of treatment.  
 
 
Conclusion: Differences in hypoxia between weeks 0-2, 2-5 
and 0- 5, respectively, show statistical significance. This is 
crucial in the process of re-oxygenation. As concluded in 
previous works, change of treatment strategy, e.g. by means 
of dose escalation might be most efficient early during 
treatment. However further analysis, with more patients and 
correlation to disease-free and overall-survival are needed. 
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Purpose or Objective: There is increasing interest in 
maximising data extraction from the multimodality imaging 
performed in cancer patients in order to predict treatment 
outcomes. This is particularly relevant in Oropharyngeal 
cancer where concomitant chemoradiotherapy is the 
standard treatment in stage III and IV disease but there is 
significant variation in patient outcomes and both treatment 
intensification and de-intensification strategies are being 
investigated.  
The aim of this prospective pilot study was to look at how 
data obtained from pre- and per-treatment 18F-FDG-PET/CT 
scans and textural features from pre- and per-treatment 
contrast enhanced planning CT scans correlated with known 
prognostic indicators including smoking history and HPV 
status.  
 
Material and Methods: Eligible patients included those 
undergoing primary concomitant chemoradiotherapy for 
Stage III/IV SCC of the Oropharynx. Each patient underwent a 
contrast enhanced planning CT and an 18F-FDG-PET/CT scan 
immobilised in the treatment position prior to the start of 
treatment and then again after 8-10 fractions of 
radiotherapy. The SUVmax and SUVmean were recorded on 
both the pre- and per- treatment 18F-FDG-PET/CT. Texture 
analysis was performed using TexRad software on both the 
pre- and per-treatment planning CT scans. The smoking 
history for each patient was established on enrolment to the 
study and HPV status was determined using p16 IHC on biopsy 
of the primary tumour. Ethical approval was gained from the 
relevant bodies. 
 
Results: Eighteen patients were recruited. HPV status was 
positive in 13 patients and negative in 5 patients. The 
SUVmax/mean in HPV negative patients was 21.6/13.3 on the 
pre-treatment 18F-FDG-PET/CT versus 15.2/10.5 for HPV 
positive patients (p= 0.09/0.25). Pre-treatment CT texture 
analysis showed a difference in the normalised entropy 
between the two groups with a significant difference 
detected using the smallest filter (p=0.04). The 
SUVmax/mean on the pre-treatment 18F-FDG-PET/CT for 
patients with no or minimal smoking history (<10 years) was 
13.7/9.5 versus 19.1/12.9 for those with a smoking history of 
>10years (p= 0.1/0.13). No significant difference in the 
entropy/entropy ratio between the two groups was detected. 
No significant differences were shown in the change in SUV or 
entropy ratio between the pre-and per-treatment scans in 
any of the groups. 
 
Conclusion: These results suggest differences in the imaging 
characteristics between patients in different prognostic 
categories may be detected at the pre-treatment stage and 
are worthy of further investigation in a larger patient cohort 
and may in the future add further information to that 
provided by the molecular profiling of tumours. This study 
did not show any significant differences in the data obtained 
between patients in terms of their early response to 
treatment however this data can be revisited once follow up 
data for this patient cohort matures. 
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Purpose or Objective: This study looking for the prognosis 
value of over-expression of EGFR and/or COX-2 in patients 
with locally advanced squamous cervical carcinoma (LASC). 
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Material and Methods: 118 patients with FIGO IB2-IVA st. 
were treated with RT-CT radical (Tab A). Anti-EGFR 
monoclonal Ac.(clone H11 Ref. M-3363 -Dako). The 
Immunoreactivity was based on semiquantitative analysis 
scored as the % of stained cells. Moderate/high EGFR staining 
(>31 to ≥70%, respectively) were considered (+). Anti -COX-2 
monoclonal Ac. (clone CX-2949 Ref. M361 - Dako). 
Moderate/high COX-2 staining (>31 to ≥70%, respectively) 
were considered (+). Pelvic radiotherapy in 21 patients with 
RT-3D, dose 46 Gy. In 97 cases (82%) was extended to the 
para-aortics, dose 45 Gy. A single application of LDR BCT was 
delivered on 51 pts (43.5%). Isotope: Cs-137. Dose to point A: 
30 Gy. HDR BCT to 64 pts (54%) in 3 or 4 applications. 
Isotope: Ir-192; Microselectron®. Dose 30 Gy to point A (33 
pts) and a dose of 7 Gy to CTV/application (31 pts). CT: 
CDDP: 40 mg/m2/ iv weekly.  
 
Results: Mean time follow-up for 118 pts: 56.5 months ±DS 
10.5 (median 56). Mean time follow-up of lost pts (8): 48 
months ± DS 10.5 (median 46). Clinical characteristics and 
treatments in Tab nº1 and º2.  
 
 
 
EGFR: 33 pts without overexpression vs. 85 pts (72%) with 
overexpression. COX-2: 77 pts without overexpression vs 41 
(35%) with over-expression. 24% were EGFR/COX-2 (+), 58% 
were EGFR (+)/ COX-2 (-) or vice versa and 18% were EGFR/ 
COX-2 (-). 94 pts (80%) with CR, 22 pts with PR and 2 pts 
stabilisation. Actuarial OS at 3/5 yrs:79% (CI 95%:70-85) and 
77% (CI 95%:68-84). Actuarial DFS at 3/ 5 yrs:71% (CI 95%: 62-
78) for both. Actuarial PFFS at 3/5 yrs:81% (IC 95%: 72-87) for 
both. We observed 13 local failures, 4 regional failures, 6 
joint failures; 1 pure para-aortic failure, 9 exclusive 
metastasis to distance. We found that EGFR overexpression is 
age related >50 yrs old (p=0.01). The most advanced stages 
(III-IVA) are related to joint overexpression of both markers 
(p=0.02). Tab nº3 and º4 summarize our results.  
 
 
The EGFR overexpression or COX-2 or both together, did not 
reach significance in the univariate analysis for DFS and PPFS. 
 
Conclusion: We did not find an association between 
overexpression of EGFR and/or COX-2 regarding the DFS and 
PPFS, despite being described in literature that these 
markers play a role in tumoral biology and in its 
evolution.There is a need for homogeneous, prospective 
studies with a standardized determination for these markers. 
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Purpose or Objective: We previously reported that the 
disruption of MEK/ERK/c-Myc axis affects in vitro and in vivo 
growth, angiogenic signaling and radiosensitivity of the 
embryonal rhabdomyosarcoma (ERMS) cell lines. Herein, we 
investigated the role of c-Myc in vitro invasion, migration, 
neo-angiogenesis and radioresistance of ERMS cells.  
 
Material and Methods: RD and TE671 cells expressing the c-
Myc dominant negative MadMyc chimera protein or shRNA-c-
Myc were used. 
 
Results: c-Myc depletion affected ERMS cells in vitro 
migration and invasion abilities by reducing the sialylation 
levels of NCAM and decreasing the MMP-9, MMP-2 and u-PA 
gelatinolytic activity. Although c-Myc down-regulation 
affected HIF1-α, VEGF and TSP1 proteins expression, no 
effects were seen on in vitro neo-angiogenesis. Rapid, but 
not prolonged, c-Myc down-regulation radiosensitized ERMS 
cells by impairing the expression of DSB repair proteins such 
as RAD51 and DNA-PKcs but not Ku80. 
